New study reveals cellular communication driving chemotherapy resistance in pancreatic cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 07:16 ET (22-Jun-2026 11:16 GMT/UTC)
Researchers have uncovered a key cellular communication network that drives resistance to gemcitabine in pancreatic cancer. By integrating bulk, single-cell and spatial transcriptomics with experimental validation, the study identifies crosstalk between PRRX2-positive epithelial cells and SPP1-positive macrophages as a central mechanism promoting tumor aggressiveness and poor prognosis. The findings highlight new biomarkers and suggest potential combination treatment strategies to overcome chemotherapy resistance.
New research published by Wiley online in CANCER indicates that psychosocial factors—which influence how a person perceives, interprets, and reacts to their surroundings—do not affect an individual’s risk of developing cancer.
ROS serve as crucial mediators of redox homeostasis, playing decisive roles in diverse pathological processes. While inorganic sonosensitizers for SDT represent significant advances in ROS-based therapeutics, developing US-responsive sonosensitizers with optimal biocompatibility, and initiating innovative treatment strategies remains a substantial translational challenge. In this work, researchers demonstrate that FeOOH nanorods function as exceptional tribocatalysts capable of efficiently converting vibrational mechanical energy into therapeutic effects through sono-tribocatalytic activation.
A randomized crossover pilot study conducted by researchers at the University of Sherbrooke and the Research Centre on Aging in Quebec, Canada, investigated whether moderate-to-high-intensity aerobic exercise performed the day before chemotherapy could influence cancer-related fatigue and active versus sedentary behaviors in the days following treatment. The study, published in Translational Exercise Biomedicine (ISSN: 2942-6812), an official partner journal of International Federation of Sports Medicine (FIMS), provides preliminary evidence that pre-chemotherapy exercise is safe and may offer modest benefits for fatigue management.